Customize your JAMA Network experience by selecting one or more topics from the list below.
Since February 2004, CDC has recommended that 7-valent pneumococcal
conjugate vaccine (PCV7), marketed as Prevnar® and manufactured by Wyeth
Vaccines (Collegeville, Pennsylvania), be administered to healthy children
on an abbreviated schedule to conserve the limited supply.1-3 Production
capacity has been increased, and supply is now sufficient to meet the national
demand for vaccine on the routine, 4-dose schedule. Effective immediately,
CDC, in consultation with the Advisory Committee on Immunization Practices,
the American Academy of Family Physicians, and the American Academy of Pediatrics,
recommends that providers resume administration of PCV7 according to the routine
A vaccination schedule is provided for children who are incompletely
vaccinated. The highest priority for catch-up vaccination is to ensure that
children aged <5 years at high risk for invasive pneumococcal disease because
of certain immunocompromising or chronic conditions (e.g., sickle cell disease,
asplenia, chronic heart or lung disease, diabetes, cerebrospinal fluid leak,
cochlear implant, or human immunodeficiency virus infection) are fully vaccinated.
Second priorities include vaccination of healthy children aged <24 months
who have not received any doses of PCV7 and vaccination of healthy children
aged <12 months who have not yet received 3 doses.
Because of the frequency of health-care provider visits by children
during their first 18 months, catch-up vaccination might occur at regularly
scheduled visits for most children who receive vaccines from their primary-care
providers. Programs that provide vaccinations but do not see children routinely
for other reasons should consider a notification process to contact undervaccinated
Providers with questions about obtaining Prevnar® should contact
Wyeth’s customer service department, telephone 800-666-7248. For public-purchased
vaccine, including vaccines used in the Vaccines for Children Program, providers
should contact their state/grantee immunization projects to obtain vaccine.
These projects should contact their project officers at the National Immunization
Program at CDC for information regarding vaccine supply.
Pneumococcal Conjugate Vaccine Shortage Resolved. JAMA. 2004;292(18):2210. doi:10.1001/jama.292.18.2210
Coronavirus Resource Center
Create a personal account or sign in to: